Compare AstraZeneca plc (AZN) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Quanta Services Inc — how do they compare? AstraZeneca plc trades at $166.87 (market cap $253.13B), while Quanta Services Inc trades at $664 (market cap $99.18B). The key difference: AstraZeneca plc is far larger — about 2.6× Quanta Services Inc's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | PWR | |
|---|---|---|
Market Cap | $253.13B | $99.18B |
Sector | Health | Industrials |
52-Week High | $209.48 | $785.24 |
52-Week Low | $137.44 | $372.50 |
Enterprise Value | $279.37B | $105.14B |
Dividend Yield | 1.92% | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Quanta Services (PWR) trades at $646.70, down 1.8% with a bearish technical signal despite strong fundamentals. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue growth remains robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins are thin at 3.67%. Analyst consensus is strongly bullish with a $836.80 price target, representing 29% upside potential from current levels.
PWR offers exposure to infrastructure spending tailwinds from AI data centers and grid modernization, but faces valuation concerns with a P/E of 88.7. The stock's premium multiple requires flawless execution amid aggressive capital expenditure plans. Near-term technical weakness contrasts with strong institutional support and positive earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
